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ABSTRACT 
 
Synthetic Strategies Toward Tetrahydrofurans Involving Double Diastereoselective 
Nucleophile-Promoted Aldol-Lactonizations and Subsequent Applications to Bioactive 
Natural Product Synthesis. (April 2009) 
 
Kevin Michael Arendt 
Department of Chemistry 
Texas A&M University 
 
Research Advisor: Dr. Daniel Romo 
Department of Chemistry 
 
Novel synthetic strategies towards the formation of tetrahydrofurans and their 
subsequent application to bioactive natural products have been explored.  More 
specifically, a method for invoking double-diastereoselectivity in the formation of 
tetrahydrofuran-fused β -lactones through nucleophile-catalyzed aldol-lactonization 
(NCAL) has been developed.  By employing a chiral catalyst, such as OTMS-quinidine 
or OTMS-quinine, coupled with a chiral aldehyde acid substrate, we have been able to 
successfully override the inherent substrate stereochemical bias to access either 
diastereomeric product as the major adduct.  This new methodology is being applied to 
construction of the tetrahydrofuran fragment of the cytotoxic agent, haterumalide NA.  
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NOMENCLATURE 
9-BBN    9-borabicyclo[3.3.1]nonane 
AcOH    Acetic Acid 
amu    Atomic Mass Unit 
CH2Cl2 Dichloromethane 
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m-CPBA meta-Chloroperoxybenzoic Acid 
mmol Millimoles 
Na2SO4 Sodium Sulfate 
NaHCO3 Sodium Bicarbonate 
NaS2O3 Sodium Thiosulfate 
NCAL Nucleophile-Catalyzed Aldol-Lactonization 
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NH4Cl Ammonium Chloride 
NMR Nuclear Magnetic Resonance 
nOe Nuclear Overhauser Effect 
PPh3 Triphenylphosphine 
ppm Parts per Million 
sat’d Saturated 
PPY 4-(pyrrolidin-1-yl)pyridine 
TBDPS tert-Butyldiphenylsilyl 
THF Tetrahydrofuran 
t-Bu tert-Butyl 
TLC Thin Layer Chromotography 
OAc-QD Acetyl Quinidine 
OTMS-QD Trimethylsilyl Quinidine 
OAc-QN Acetyl Quinidine 
OTMS-QN Trimethylsilyl Quinine 
µM Micromolar 
nM Nanomolar 
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This thesis follows the style of Journal of the American Chemical Society. 
CHAPTER I 
INTRODUCTION 
Chemistry is a dynamic science where new discoveries are constantly being made.  This 
is especially true in synthetic organic chemistry as new reactions that produce a desired 
product in higher yield and with greater efficiency are sought.  An area that has garnered 
considerable interest in the past half century is that of complex natural product total 
synthesis due to the great potential these compounds have as leads for drug discovery.  
Efficient synthesis of these intriguingly complex molecules is a great challenge to 
chemists world-wide.  To address this problem, researchers have developed versatile 
synthetic intermediates, which can be easily manipulated into an array of functionalities.  
One such intermediate is the β-lactone (2-oxetanone) which is attracting growing interest 
for both synthesis and biology and is the focus of our research group.  
 
Utility of β-lactone functionality 
The β-lactone moiety has been shown quite successfully to be a useful intermediate in 
natural product total synthesis because it can easily be transformed into a number of 
different functionalities (Scheme 1.1).1  There are many examples of natural product 
total syntheses in which β -lactones have been utilized as intermediates to facilitate the 
synthetic sequence (Figure 1.1).  In the past, chemists have often used epoxides as 
synthetic intermediates because their inherent ring strain (27.8 kcal/mole) makes 
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Figure 1.1.  Natural products and precursors synthesized employing β-lactone intermediates (Atoms 
derived from the β-lactone are boxed).1-24 
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Scheme 1.1.  Facile Transformations of β-Lactones.25 
 
 
 
them reactive to a variety of reagents (Figure 1.2).  However, β-lactones, while slightly 
less strained (22.8 kcal/mole), are structurally quite similar to aldol products.  The 
combination of ring strain and structure allow β-lactones to undergo facile conversion in 
a stereospecific fashion.  In addition, β -lactones are found in a number of enzyme 
inhibitors which suggests the possibility of developing cellular probes bearing this 
functionality to identify lead compounds as small molecule inhibitors of various cellular 
proteins important to human health and disease.26  
 
 
Figure 1.2.  Structural comparison of β-lactones with epoxides and aldol products. 
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Synthetic application towards natural products 
Natural products, in the most general of definitions, are chemical compounds (typically 
<1500 amu) which are produced by living organisms.  Many of these molecules possess 
bioactivity, and as a result have historically been excellent leads for novel drug 
discovery.  A prime example is the isolation of the antibiotic penicillin from a fungus of 
the genus Penicillium.27  Since its discovery several analogs possessing greater potency, 
such as ampicillin and methicillin, have been synthesized which are used to treat a 
variety of bacterial infections.28  However, quantities of the compound that can be 
obtained from natural sources are often insufficient for further biological studies.  To 
counter this imbalance, chemists continue to develop a number of strategies to 
synthesize natural products in the laboratory, ideally with increased efficiency.  Often 
these natural products have multiple stereocenters which need to be synthesized with the 
correct stereochemical relationships, both relative and absolute, for the target molecule 
to maintain desired medicinal effects.  Setting these stereocenters often involves multiple 
steps resulting in relatively low yields of the desired product.  The low yield may be 
attributed to the lack of stereochemical control during the reactions producing a number 
of enantiomers or diastereomers, ultimately reducing the yield of the desired product.  
Thus chemists are constantly searching for new, more stereoselective synthetic strategies 
to obtain a particular enantiomer or diastereromer.29  My current research involves 
developing a synthetic strategy that involves setting not only one but two stereocenters 
with high stereoselectivity, utilizing a double diastereoselective strategy.9  Chemists 
have often used this strategy with various chiral catalysts to override the inherent 
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stereochemical bias of a chiral substrate to yield the desired stereoisomer.13,30  With the 
aid of Dr. Daniel Romo and my mentor Kay Morris, I applied this strategy for the first 
time to the Nucleophile-Catalyzed Aldol-Lactonization (NCAL) reaction, a method 
developed in the Romo group,9 to prepare tetrahydrofuran-fused β-lactones (Figure 1.3). 
 
 
Figure 1.3.  Generic γ-substituted tetrahydrofuran-fused β-lactone. 
 
 
An overview of the haterumalides 
The haterumalides have been studied due to their interesting biological activity.  
Haterumalide B was first isolated by Ueda and Hu from the Okinawan ascidian 
Lissoclinum spinosula.31  Initial assays showed that haterumalide B completely inhibited 
the cellular division of fertilized sea urchin eggs at a concentration of 18 nM.32  Later 
studies revealed that this compound inhibits apothecial formation in fungi.31  Around the 
same time Uemura et. al. isolated haterumalides NA, NB, NC, ND, and NE from a 
similar Okinawan sponge Ircinia spinosula.32  Each haterumalide is a fourteen-
membered, halogenated macrolide, containing a tetrahydrofuran (THF) ring (Figure 1.4).   
Many of the haterumalides act as antifungal agents and are able to completely suppress 
apothecial formation at concentrations ranging from 0.4-1.0 µM.33-35  However, the most 
potent member is haterumalide NA methyl ester.   
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Figure 1.4. Structure and biological activity of the haterumalides. 
 
 
Table 1.1 compares the cytotoxicities of haterumalide NA methyl ester with two 
synthetic chemotherapy drugs.33  Surprisingly, the natural product showed stronger 
potency to many of the cell lines, including human lung cancer NCI-H460, than the 
anticancer medications.  This data encourages the use of the haterumalides as lead 
compounds in the development of novel anticancer drugs. 
 
Table 1.1.  Cytotoxicity of haterumalide NA methyl ester, cisplatin, and adriamycin with IC50 values (µM) 
 HOPI8 NCI-H460 A498 PC-3 DLD-1 HCT116 P388 P388/ADR 
Haterumalide NA 
Methyl ester 0.739 0.135 0.335 0.539 0.141 0.292 0.408 0.621 
Cisplatin 4.08 0.600 4.01 4.01 2.11 2.23 0.0754 0.271 
Adriamycin 0.159 0.00823 0.166 0.357 0.910 0.0629 0.0253 5.79 
 
 
Interestingly the enantiomer of haterumalide NA (ent-haterumalide NA), derived from 
the soil bacterium Serratia malcesens, has been shown to decrease the formation of lipid 
droplets in adipocyte cells.36  Elevated triglyceride levels in the blood stream decrease 
the efficiency of metabolism, ultimately giving rise to cardiovascular disease, diabetes, 
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obesity, and hypertension.  Recent chemical genetic studies of ent-haterumalide have 
shown that this compound inhibits protein phosphatase 2A (PP2A).37  PP2A regulates 
signal transduction cascades that produce vital biological events such as cell cycle 
transition and differentiation.  Blocking PP2A inhibits preadipocytes from undergoing 
adipogenesis and maturing into triglyceride-containing adipocytes.37  However, it is 
expected that haterumalide NA, as well as the other haterumalides, would have varying 
cellular receptors owing to their altered substitution and stereochemistry.  Thus, our 
group is interested in the haterumalides as useful biological probes for further 
identification of novel receptors.  Haterumalide NA is the main member of interest due 
to its unique structure, potent biological activity, and potential to uncover structure-
activity relationships of derivatives with their targets.  
 
The relative and absolute stereochemical assignments of haterumalide NA were 
originally determined by extensive 2D-nuclear magnetic resonance (NMR) experiments 
as well as studies of Mosher ester derivatives.  The relative configuration of the 
tetrahydrofuran ring was acquired from nuclear Overhauser effect spectroscopy (nOe) 
correlations as well as by comparison to the structurally similar pectenotoxin38 and 
isolaulimide.39  However, later syntheses by both Kigoshi40 and Snider41 determined that 
all of the assignments, except for the C14 hydroxyl group, were inverted.  Subsequent 
total synthesis by Hoye42 confirmed the revised stereochemical assignments of 
haterumalide NA.  Three other recent syntheses have focused on forming the C8-C9 
bond in novel ways (Scheme 1.2).  Kigoshi et. al. reported a second generation total 
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synthesis of haterumalide NA employing 9-BBN dimer in a Suzuki-Miyaura coupling 
and a nickel-catalyzed Nozaki-Hiyama-Kishi coupling as key steps in improving 
efficiency and yield of a common intermediate.43  Borhan has also published a formal 
synthesis of haterumalide NA via an unprecedented chromium-mediated 
macrolactonization.44  Roulland recently published a novel synthesis of haterumalide NA 
in which he uses a dichloro-olefin moiety to install the chlorine at C8 via a Suzuki-
Miyaura coupling reaction.45 
 
Scheme 1.2.  Novel synthetic scheme for C8-C9 and C10-C11 bond formations of Haterumalide NA. 
 
 
 
While these syntheses possess admirable qualities, the methodology which we have 
proposed would, in one step, create not only the THF ring setting three key 
stereocenters, but also a β-lactone which is ‘spring-loaded’ to undergo facile 
transformation to access the natural product haterumalide NA. 
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CHAPTER II 
 
METHODS 
 
General methods 
All non-aqueous reactions were carried out under nitrogen atmosphere in oven-dried 
glassware (120 °C).  Dichloromethane (CH2Cl2) and diethyl ether (Et2O) were obtained 
from a solvent purification system (alumina). Tetrahydrofuran (THF) was distilled from 
a sodium/benzophenone ketyl still.  Triethyl amine (Et3N) and diisopropylethyl amine (i-
Pr2NEt) were distilled from calcium hydride immediately prior to use.  Deuturated 
solvents were purchased from either Aldrich or Cambridge Isotopes and used as 
received.  All other chemicals were purchased from Aldrich or Acros and used without 
purification.  Reactions were monitored by thin layer chromatography (TLC) on silica 
Merck 60 F254 (0.25 mm).  TLCs were stained using potassium permanganate and 
annisaldehyde stain.  Flash column chromatography was carried out using silica (60 Å, 
230-400 Mesh) as a stationary phase as described by Still.46 
 
1H NMR characterization was performed on 300 MHz and 500 MHz spectrometers.  13C 
NMR characterization was performed on 75 MHz and 125 MHz spectrometers.  1H 
chemical shifts are reported as δ values in ppm relative to residual CHCl3 (7.27 ppm).  
1H NMR coupling constants (J) are reported in Hertz (Hz), and multiplicities are 
indicated as follows: s (singlet), d (doublet), t (triplet), q (quartet), dd (doublet of 
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doublets), dt (doublet of triplets), dq (doublet of quartets), tt (triplet of triplets), m 
(multiplet), bs (broad singlet).  Deuteriochloroform (CDCl3) served as internal standard 
(77.23 ppm) for all 13C spectra.  Enantiomeric excess was calculated via HPLC analysis 
using a HPLC equipped with Chiralcel OD and Chiralpak IA columns.  Infrared spectra 
were obtained as thin film on NaCl plates on a FTIR spectrometer.  Vibrational 
frequencies are expressed in cm-1.  Mass spectra were obtained at the Laboratory for 
Biological Mass Spectrometry at Texas A&M University. 
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CHAPTER III 
 
RESULTS AND DISCUSSION 
 
NCAL process 
Scheme 3.1. Proposed Mechanism For Formation of Bicyclic β-Lactones.47 
 
 
In the most general case, the intramolecular nucleophile-catalyzed aldol-lactonization 
(NCAL) process affords β-lactones fused to another cyclic moiety such as cyclopentane 
or a tetrahydrofuran.  A thermal [2 +2] cycloaddition involving a ketene is plausible 
instead of the proposed NCAL pathway (Scheme 3.1).48  Previous studies within our 
group have provided evidence in favor of a NCAL reaction over a [2 +2] cycloaddition 
since employing a chiral amine catalyst leads to the formation of bicyclic systems in 
high enantiomeric purity.9  While the precise details of the NCAL process remains 
ambiguous and a competitive pathway could invoke ketene formation leading to a 
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reduction of enantiomeric purity, it is a minor pathway.  Reaction through a ketene 
intermediate does not require involvement of the chiral nucleophile and therefore yields 
racemic β-lactones.  However, addition of OAc-QD afforded bicyclic β-lactones in 92% 
enantiomeric excess; thereby providing support for an enantioselective NCAL pathway.  
Optimization of the conditions used, namely employing Mukaiyama’s reagent as an 
activating agent coupled with OAc-QD acting as a chiral nucleophile along with achiral 
Hünig’s base, ultimately led to the formation of β -lactones with excellent 
enantioselectivity (98%).30  The β-lactone was formed with similar but reversed levels of 
asymmetric induction by using the pseudo-enantiomer OAc-QN as the chiral nucleophile 
(Figure 3.1). 
 
 
Figure 3.1. Illustration of accessibility of either enantiomer in high selectivity by employing chiral 
catalysts. 
 
 
Initial studies 
Herein, we report the development of a methodology for the synthesis of 
tetrahydrofuran-fused β -lactones via a novel double-diastereoselective NCAL process.  
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The required aldehyde acid precursor 3.19 was prepared by a five step sequence starting 
with commercially available 4-phenyl-1-butene (Scheme 3.2).  The alkene was first 
reacted with meta-chloroperoxybenzoic acid (m-CPBA) to form racemic epoxides 
3.15a/3.15b; which were subsequently subjected to Jacobsen’s hydrolytic kinetic 
resolution to afford the desired epoxide 3.15a.  Ring-opening with vinyl 
magnesiumbromide followed by addition of iodoacetic acid gave alkene-acid 3.18.  
Oxidation via ozonolysis in conjunction with a reductive work-up led to aldehyde acid 
3.19. 
 
Scheme 3.2. Synthetic Route for Aldehyde Acid 3.19. 
 
The reactions proceeded smoothly with the assumption that high enantioselectivity was 
achieved in the hydrolytic kinetic resolution step.  However, once we began initial 
studies towards β-lactone formation it was discovered that aldehyde acid precursor 3.18 
was in fact a racemic mixture.  The low enantioselectivity observed was due to the 
second step in the sequence, specifically the hydrolytic-kinetic resolution step, affording 
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little to no resolution of the two enantiomers 3.16a/3.16b.  A closer inspection of 
Jacobsen’s mechanism for hydrolytic-kinetic resolution provided insight to solve this 
problem. 
 
Hydrolytic kinetic resolution: A mechanistic study 
The basis for hydrolytic kinetic resolution is that one enantiomer of the epoxide reacts 
preferentially to the other enantiomer via ring-opening with water to resultant diol.  This 
reaction is catalyzed by a Co(III)-salen catalyst and has been found to proceed through a 
bimetallic mechanism similar to other asymmetric ring-opening reactions (Scheme 
3.3).49 
 
Scheme 3.3. Dominant Catalytic Cycle in HKR Reactions Catalyzed by Co-X (X ≠ OH). 
 
 
Jacobsen found that the catalyst equally bound to either enantiomer of the epoxide and 
after detailed studies concluded that the high selectivity observed in hydrolytic kinetic 
resolution results from a counter-ion effect.  The initial rate at which the counter-ion of 
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the catalyst is displaced with water influences the rate of the reaction and ultimately the 
selectivity.  Since the reaction proceeds through coordination of the epoxide to the Lewis 
acidic cobalt (X ≠ OH) the Lewis basic cobalt species (X = OH) is the rate determining 
step as well as the stereochemical setting step.  A balance for production of each cobalt 
species is the key to high enantioselectivity for this reaction.  If the initial addition of the 
counter-anion to the epoxide is either too slow or too fast the reaction will proceed at a 
low rate, as in our previous results.  The fastest rates can be achieved when a balance for 
counter-anion addition is obtained.  Thus, faster addition of water provided this balance 
and led to maximum resolution rates giving high enantiomeric ratios (16:1 → 99:1 er) of 
the unreacted epoxide and corresponding diol products. 
 
Double-diastereoselective NCAL 
Use of OAc-QD or OAc-QN gave similar levels of enantio-enrichment but with reversal 
in the absolute stereochemistry.  This asymmetric NCAL process was amenable to a 
variety of carbocyclic, bicyclic β-lactones, which provided a promising starting point for 
further application toward a double-diastereoselective process.  Substitution at the β-
position led to >19:1 diastereoselectivity (Figure 3.2).  However, γ- or δ-substituents 
gave bicyclic products with little to no diastereoselectivity.  Although low 
diastereoselectivities were obtained with γ- or δ-substitution, the high enantioselectivity 
observed in the previous NCAL studies prompted the pursuit of double-
diastereoselective NCAL methodology.   
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The hypothesis was that by using one enantiomer of the substrate obtained prior to 
subjecting to the NCAL, two isomereric products would be eliminated.  The asymmetric 
nucleophile would then control the stereochemistry at the fused positions in the bicyclic 
system while also overcoming the inherent bias exhibited by the substrate (Scheme 3.4).   
 
 
Figure 3.2. Contrast between enantioselectivity and diastereoselectivity.  Relative diastereoselection for 
carbocycle-fused β-lactones bearing β-, γ-, and δ-substitution. 
 
 
In 1985 Sharpless defined the concept of using a chiral catalyst to override the inherent 
stereochemical bias of the substrate, leading to a so-called “mismatched” case which has 
been practiced by several chemists, primarily Masamune.29  Similarly, a different 
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catalyst can be employed which displays the same selectivity as the substrate, thereby 
making a “matched” case. 
 
As previously shown, high enantioselectivity can be achieved during the NCAL process 
with an optically active catalyst (Figure 3.1).  Theoretically, utilizing a single enantiomer 
of the aldehyde acid should provide both high enantioselectivity as well as high 
diastereoselectivity.  The use of racemic or achiral reactants leads to a variety of  
 
Table 3.1. Theoretical outcome for NCAL reactions 
 
 
expected stereochemical results, which are outlined in Table 3.1.  Based on these 
predictions, we began screening a variety of conditions for the NCAL reaction that 
would lead to the desired enantio- and diastereoselectivity. 
 
Scheme 3.4. Rationale for OTMS-QD control of enantioselectivity at fused carbons. 
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The enantioselectivity can be explained by catalyst conformation shown above.  In the 
scheme presented above, OTMS-QD directs the aldehyde acid to react in a conformation 
that positions the substrate further away from the bulky aryl group as well as reducing 
unfavorable electronic interactions between the ammonium enolate and the aromatic 
system.  This results in carbocycle- or tetrahydrofuran-fused β-lactone 3.38 with the 
trans relative configuration for all three stereocenters; and the absolute stereochemistry 
being (1S,2R,5S).  The pseudo-enantiomer of OTMS-QD, OTMS-QN, directs the 
formation of the ammonium enolate in a similar fashion; however, the absolute 
stereochemical outcome of bicyclic β-lactone 3.39 is reversed to provide the (1R,2S,5S), 
with the cis-diastereomer favored. 
 
NCAL optimization 
With both racemic and optically active aldehyde acid 3.19 in hand, we began to 
investigate a variety of conditions to facilitate a double-diastereoselective nucleophile-
catalyzed aldol-lactonization process.  To observe the substrate’s inherent 
stereochemical bias a control experiment was run by adding racemic aldehyde acid 3.19 
to Mukaiyama’s reagent and triethyl amine, the latter reagent acted as both a base and an 
achiral nucleophile (Scheme 3.5). 
 
Scheme 3.5. Double-Diastereoselective Nucleophile-Catalyzed Aldol-Lactonization. 
 
  19 
 
The reaction afforded tetrahydrofuran-fused β -lactones 3.40a/3408b in moderate yield 
(39%) with a slight preference for the trans-bicyclic system 3.40a with a diastereomeric 
ratio of 2:1.  Based on earlier research involving carbocycle-fused β-lactones, in which 
both good enantioselectivity and diastereoselectivity could be achieved, we chose to 
employ OTMS-QN and OTMS-QD to act as chiral nucleophiles (Figure 3.3)30, while 
changing the base to an achiral amine i-Pr2NEt.   
 
However, the results obtained from our experiments revealed that oxygenated systems 
behave and react differently than their all carbon analogs. 
 
 
Figure 3.3. Chiral nucleophiles studied in the NCAL process. 
 
Using the same conditions as previously reported for carbocycles, the NCAL process 
afforded tetrahydrofuran-fused β -lactones in poor yield (Table 3.2).  Even more 
intriguing was the fact that the chiral cinchona alkaloid catalysts employed in these 
experiments displayed little to no diastereoselectivity for the desired bicyclic systems.  
An attempt at optimization using the quinidine and quinine derived nucleophiles with 
varying reaction times showed no improvement in β-lactone yield or in 
diastereoselectivity.  
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Entry 4 does show that the OTMS-QD provided catalyst control to a certain extent; 
however, the overall tetrahydrofuran-fused β -lactone yield was still too low to be 
considered a practical process.   
 
Table 3.2. Optimization results for double-diastereoselective NCAL process 
 
 
Changing the substituent on the aldehyde acid to a protected alcohol as well as utilizing 
the more nucleophilic catalyst tetramisole led to a significant decrease in 
tetrahydrofuran-fused β -lactone (entry 6).50  Further optimization is required for this 
reaction to achieve the high double-diastereoselectivity and higher yields are needed for 
a practical synthetic methodology. 
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CHAPTER IV 
SUMMARY AND CONCLUSIONS 
 
We have shown that a double-diastereoselective bis-cyclization can be afforded 
employing the nucleophile-catalyzed aldol-lactonization process with both chiral 
substrates and chiral nucleophiles (Lewis bases).  Previously, several β-lactone-fused 
carbocycles have been formed in good yield with high diastereomeric ratios; however, 
certain substituted substrates e.g. δ -substituted aldehyde acids led to low 
diastereoselectivity.  Tetrahydrofuran-fused β -lactones have been formed via this 
double-diastereoselective NCAL process; however, the yields are low and the reactions 
provide little to no diastereoselectivity.  The major byproducts of these reactions are α,β-
unsaturated aldehyde 4.1 as well as α,β-unsaturated acid 4.2 (Figure 4.1). 
 
 
Figure 4.1. Major byproducts formed in asymmetric NCAL reactions. 
 
This result was not observed in the carbocyclic systems because the substrate did not 
possess a heteroatom and therefore less prone to β-elimination or condensation.  For the 
tetrahydrofuran systems however, the oxygen at the γ-position in the aldehyde acid pulls 
electron density away from the carbons at the α - and β-positions, thus causing the β-
protons to become more acidic and therefore more susceptible to β -elimination due to 
excess base (Scheme 4.1).  In a similar manner, α,β-unsaturated acid 4.2 is formed by 
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ring-opening and subsequent elimination of the product β -lactone or through an aldol 
condensation process. 
 
Scheme 4.1. Mechanistic rationale for formation of byproducts in the NCAL process (X = OAc, OTMS).  
Two possible routes for the formation of 4.2 can be envisioned.  Note that elimination processes for both 
4.1 and 4.2 could proceed via E1cb mechanisms (not shown). 
 
 
Basic conditions are required to activate the aldehyde acid substrate employed in the 
NCAL reaction.  Due to the oxygenated substrate’s ability to undergo facile β -
elimination, perhaps a bulkier base could be employed that would be basic enough to 
activate the aldehyde acid yet too sterically hindered to access protons available for β-
elimination. 
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Ongoing studies 
Continuing investigations into finding optimal conditions for a double-diastereoselective 
NCAL process employing oxygenated substrates is currently being pursued.  Once 
sufficient optimization is achieved, the synthesis of the side chain of haterumalide NA 
will commence.  The proposed synthetic route is outlined in Scheme 4.2.  
Diastereomerically pure tetrahydrofuran-fused β -lactone 4.3 will be treated with N, O-
dimethylhydroxylamine to form Weinreb amide 4.4.  Protection of the free alcohol with 
tert-butyldimethylsilyl chloride followed by reduction of the amide with DIBAl-H 
would afford aldehyde 4.5.  Treatment with Dess-Martin periodinane and subsequent 
Nozaki-Hiyama-Kishi coupling of a vinyl iodine species would ultimately lead to 
tetrahydrofuran fragments with high diastereoselectivity for the desired diastereomers, 
i.e. 4.6.40 
 
Scheme 4.2. Proposed synthetic route towards THF fragment of haterumalide NA. 
 
 
Preparation of the tri-substituted tetrahydrofuran 4.6 via the NCAL process constitutes 
an innovative synthetic route to the eastern hemisphere of haterumalide NA.  Further 
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manipulation of the THF ring and subsequent macrolactonization would ultimately lead 
to the natural product.  Application of the double-diastereoselective NCAL reaction in 
the synthesis of haterumalide NA leads enables setting of several required stereocenters 
with great eficiency; thereby eliminating the need for late-stage reactions to establish the 
desired stereochemistry, which would lead to a less efficient and lower yielding 
synthesis. 
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APPENDIX I 
EXPERIMENTAL PROCEDURES 
  30 
 
 
 
(R/S)-2-Phenethyloxirane (3.16a/3.16b). To a 150 mL flask containing m-
chloroperoxybenzoic acid, 70% solution in water (17.7 g, 71.8 mmol) and CH2Cl2 (50 
mL) was added 4-phenyl-1-butene 3.15 (7.19 g, 8.17 mL, 54.4 mmol).  The solution was 
cooled to 0 °C and allowed to warm to 23 °C over 12 h.  The reaction mixture was 
filtered through a fritted funnel and the solids washed with sat’d NaS2O3 (5 mL).  The 
organic layer was washed with H2O (2 X 15 mL) and sat’d NaCl (10 mL).  The 
combined organics were dried over Na2SO4 and concentrated in vacuo.  The crude 
material was then purified by flash column chromatography (1:9 EtOAc:Hexanes) to 
yield racemic epoxide 3.16a/3.16b (7.73 g, 96%) as a colorless oil.  Rf  = 0.33 
(EtOAc:Hexanes = 1:9); 1H NMR (500 MHz, CDCl3) δ 7.34-7.21 (m, 5H), 2.99-2.95 (m, 
1H), 2.79 (dd, J = 3.0 Hz, 2H), 2.74 (dt, 4.0, J = 1.0 Hz, 1H), 2.46 (q, J = 2.7 Hz, 1H), 
1.90-1.82 (m, 2H); 13C NMR (125 MHz, CDCl3) δ  141.5, 128.6, 128.5, 126.2, 52.0, 
47.5, 34.5, 32.5. 
 
 
(R) 2-Phenethyloxirane (3.16a).  To a 10 dram vial was added a mixture of (R,R)-(–)-
N,N’-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediaminocobalt(II) catalyst (44.5 
mg, 0.067 mmol, 0.005 mmol), toluene (1.0 mL), and acetic acid (0.026 mL, 0.027 mg).  
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The reaction mixture was stirred open to the air for 30 min. at 23 °C then concentrated in 
vacuo.  To the red-brown residue was added (R/S) epoxide 3.16a/3.16b (2.00 g, 13.5 
mmol) and the solution cooled to 0 °C.  H2O (0.134 mL, 7.43 mmol) was added to the 
vial over 5 min. via syringe pump.  The reaction mixture was stirred for an additional 18 
h.  The oily, brown liquid was diluted with CH2Cl2 and dried over MgSO4 and 
concentrated in vacuo.  The resulting crude oil was purified by flash column 
chromatography (1:7 EtOAc:Hexanes) to yield epoxide 3.16a (0.880 g, 44%, 88% based 
on 50% max) as a red-orange oil.  Rf  = 0.39 (EtOAc:Hexanes = 1:19); Determination of 
enantiomeric excess via chiral HPLC.  Analysis of (±)-2-Phenethyloxirane 3.16: 
Chiralcel OD97.54.5 column, Hexanes: i-PrOH eluent 1.00 mL/min flow rate and a lamp 
setting of 210 nm) tr (major) = 8.659 and tr (minor) = 10.907; 1H NMR (500 MHz, 
CDCl3) δ 7.34-7.21 (m, 5H), 2.99-2.95 (m, 1H), 2.79 (dd, J = 3.0 Hz, 2H), 2.74 (dt, 4.0, 
J = 1.0 Hz, 1H), 2.46 (q, J = 2.7 Hz, 1H), 1.90-1.82 (m, 2H); 13C NMR (125 MHz, 
CDCl3) δ 141.5, 128.6, 128.5, 126.2, 52.0, 47.5, 34.5, 32.5; IR (thin film) 2860, 1496, 
700 cm-1. 
 
 
1-Phenylhex-5-en-3-ol (3.17).  To a 250 mL flask containing CuI was added 60 mL of 
Et2O.  The solution was put under N2 and cooled to -78°C.  Vinylmagnesium bromide 
was added dropwise, and the solution stirred for 30 min. while warming slightly.  To the 
brown/green mixture was added a solution of epoxide 3.16a (3.56 g, 24.02 mmol) in 40 
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mL Et2O.  The syringe was washed with Et2O and the washings added to the flask. The 
reaction stirred for 4 h at -78°C then was allowed to warm to 23 °C slowly overnight.  
The black mixture was then quenched with sat’d. NH4Cl (60 mL) and extracted with 
CH2Cl2 (3 X 50 mL).  The organic phases were combined and washed with aqueous 
sat’d NaCl, dried over Na2SO4, and concentrated in vacuo.  The crude material was 
purified by flash column chromatography (2:3 EtOAc:Hexanes) to yield alcohol 3.17 
(4.0 g, 95%) as a pale yellow oil.  Rf  = 0.33 (EtOAc:Hexanes = 2:3); 1H NMR (500 
MHz, CDCl3) δ 7.31-7.18 (m, 5H), 5.85-5.77 (m, 1H), 5.05-4.97 (m, 2H), 3.49-3.45 (m, 
1H), 3.41 (s, 1H) 2.75-2.65 (m, 2H), 2.16-2.12 (m, 2H), 1.90-1.63 (m, 2H); 13C NMR 
(125 MHz, CDCl3) δ 142.2, 134.8, 128.6, 128.5, 126.0, 118.4, 70.1, 42.2, 38.5, 32.1; IR 
(thin film) 3450, 1739 cm-1. 
 
 
2-(1-Phenylhex-5-en-3-yloxy)acetic Acid (3.18).  NaH, dissolved in mineral oil, (1.85 
g, 55.17 mmol) was washed over a fritted glass funnel with hexanes (3 X 10 mL) then 
placed in a 100 mL flask and diluted with THF (10 mL).  Iodoacetic acid (3.19 g, 17.15 
mmol) was diluted with THF (10 mL) and added to the flask.  The mixture bubbled and 
generated heat.  The reaction stirred for 30 min., then alcohol 3.17 (1.59 g, 9.03 mmol) 
diluted in THF (6 mL) was added to the flask.  The reaction mixture was put under N2 
and covered with aluminum foil and allowed to react for 72 h at 23 °C.  The grey-green 
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mixture was diluted with CH2Cl2 (200 mL) then sat’d. NH4Cl (125 mL).  The pale 
yellow solution was acidified with 10% H2SO4 to pH 1.  The mixture was extracted with 
CH2Cl2 (3 X 30 mL), the organic layers combined, dried over Na2SO4, and concentrated 
in vacuo.  The crude material was purified by gradient flash column chromatography 
(3:7→10:0 EtOAc:Hexanes) to yield alkene acid 3.18 (1.39 g, 66%) as a light brown oil.  
Rf = 0.61 (EtOAc;Hexanes = 7:3); 1H NMR (500 MHz, CDCl3) δ 7.53-7.08 (m, 5H), 
5.81 (ddd, J = 10.6, 3.6, 3.0 Hz, 1H), 5.17-4.79m (m, 2H), 4.13 (s, 2H), 3.63-3.35 (m, 
1H), 2.91-2.51 (m, 2H), 2.25-2.04 (m, 2H), 1.97-1.55 (m, 2H);  13C NMR (125 MHz, 
CDCl3) δ 174.5, 141.8, 134.0, 128.7, 128.65, 128.5, 128.5, 126.1, 118.3, 80.1, 66.3, 
38.2, 35.5, 31.6; IR (thin film) 2937, 1641, 1127 cm-1; m/z: calc. 235.1329 [M+H], 
found 235.1469. 
 
 
2-(1-oxo-5-Phenylpentan-3-yloxy)acetic Acid (3.19).  To a 50 mL flask was added 
alkene acid 3.18 (1.00 g, 4.27 mmol) in CH2Cl2 (15 mL).  This was cooled to -78°C 
under N2 for 30 min.  O3 was bubbled through the solution until blue color appeared,  ̴1 
min then O2 was bubbled through for 2 min.  Crushed PPh3 was added to the solution 
(1.11 g, 4.27 mmol).  The solution was allowed to warm slowly to 23 °C overnight under 
N2.  The reaction mixture was concentrated and re-suspended in CH2Cl2 (25 mL).  The 
aldehyde acid was purified via acid-base extraction as described below. NaHCO3 was 
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added (50 mL) and the organic layer removed.  The aqueous phase was washed with 
hexanes (1 X 50 mL) and the layers separated.  The aqueous layer was acidified with 
10% H2SO4 to pH 2 then extracted with Et2O (4 X 40 mL) and CH2Cl2 (2 X 50 mL).  
The organic extracts obtained after acidification were combined, dried over Na2SO4, and 
concentrated in vacuo to yield aldehyde acid 3.19 (0.49 g, 49%) as a viscous, colorless 
oil.  Rf  = 0.55 (EtOAc:Hexanes = 8:2); 1H NMR (500 MHz, CDCl3) δ  9.80 (s, 1H), 
7.41-7.21 (m, 5H), 4.28 – 4.16 (m, 2H), 4.26-3.99 (m, 1H), 2.73 (dq, J = 7.6, 4.2 Hz, 
2H), 2.70 (dt, J = 3.2 Hz, 2H), 2.01-1.88 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 201.7, 
174.9, 158.3, 141.1, 128.7, 128.5, 128.4, 126.3, 75.1, 66.4, 48.2, 35.5, 34.4, 34.1, 32.2; 
IR (thin film) 2929, 1723, 1127 cm-1; m/z: calc. 237.1121 [M+H], found 237.1234. 
 
 
Racemic 3-Phenethyl-2,6-Dioxabicyclo[3.2.0]heptan-7-one (3.40a/3.40b).  To a 25 
mL flask containing Mukaiyama’s reagent (59.3 mg, 0.169 mmol) was added CH2Cl2 (8 
mL) under N2 followed by Et3N (34.3 mg, 0.46 mL, 0.339 mmol).  The clear liquid 
turned pale yellow then yellow/brown.  Aldehyde acid 3.19 (227 mg, 0.0847 mmol), 
azeotroped in xylenes prior to reaction, was added as a solution in 1 mL CH2Cl2 over 1 h 
via syringe pump and the reaction stirred for 2 h at 23 °C.  The dark red solution was 
concentrated in vacuo and the crude mixture purified by flash column chromatography 
(2:8 EtOAc:Hexanes) to yield of β -lactones 3.40a/3.40b (0.044 g, 21%) as a colorless 
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oil.  3.40a:  Rf  = 0.30 (EtOAc:Hexanes = 1:4); 1H NMR (500 MHz, CDCl3) δ 7.24-7.12 
(m 5H), 5.44 (d, J = 3.5 Hz, 1H), 5.11 (t, J = 3.9 Hz, 1H), 4.11 (tt, J = 5.0, 2.5 Hz,1H), 
2.76-2.62 (m, 2H), 1.98-1.90 (m, 2H), 1.49-1.42 (m, 2H); 13C NMR (125 MHz, CDCl3) 
δ 128.6, 128.4, 126.2, 88.0, 78.7, 78.4, 36.5, 35.5, 32.3, 29.7; IR (thin film) 1831, 1600 
cm-1.  3.40b: Rf  = 0.18 (EtOAc:Hexanes = 1:4); 1H NMR (500 MHz, CDCl3) δ  7.23-
7.12 (m, 5H), 5.40 (d, J = 3.9 Hz, 1H), 5.20 (dt, J = 4.6, 1.0 Hz, 1H), 4.54 (tt, J = 5.3, 
2.5 Hz,1H), 2.74-2.60 (m, 2H), 2.14-2.09 (m, 2H), 1.82-1.71 (m, 2H); 13C NMR (125 
MHz, CDCl3) δ128.6, 128.5, 126.0, 88.1, 83.0, 79.6, 37.9, 34.8, 32.6, 29.7; IR (thin film) 
1831, 1600 cm-1; m/z: calc. 241.0835 [M+Na], found 241.1585. 
 
Optically Pure 3-Phenethyl-2,6-Dioxabicyclo[3.2.0]heptan-7-one (3.40a/3.40b).  To a 
10 mL flask containing OTMS-QD (9.9 mg, 0.025 mmol) and Mukaiyama’s reagent 
(267 mg, 0.762 mmol) was added 0.2 mL CH2Cl2 and Hünig’s base (0.13 mL, 0.100 
mmol).  Aldehyde acid 3.19 was azeotroped in xylenes prior to reaction then dissolved 
in 0.5 mL CH2Cl2 and added to the flask via syringe pump over 1 h.  The solution turned 
from yellow to dark red-brown as the reaction progressed.  The syringe was washed (2 X 
0.25 mL) with CH2Cl2 and the washings added to the reaction vessel.  The reaction 
stirred for 24 h at 23 °C then was concentrated in vacuo.  The crude material was 
purified by flash column chromatography (2:8 EtOAc:Hexanes) to yield β-lactones 
3.40a/3.40b (6.9 mg, 12.5%) as colorless oils with a 5:1 dr.  3.40a:  Rf  = 0.30 
(EtOAc:Hexanes = 1:4); 1H NMR (500 MHz, CDCl3) δ 7.24-7.12 (m 5H), 5.44 (d, J = 
3.5 Hz, 1H), 5.11 (t, J = 3.9 Hz, 1H), 4.11 (tt, J = 5.0, 2.5 Hz,1H), 2.76-2.62 (m, 2H), 
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1.98-1.90 (m, 2H), 1.49-1.42 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 128.6, 128.4, 
126.2, 88.0, 78.7, 78.4, 36.5, 35.5, 32.3, 29.7; IR (thin film) 1831, 1600 cm-1.  3.40b: Rf  
= 0.18 (EtOAc:Hexanes = 1:4); 1H NMR (500 MHz, CDCl3) δ 7.23-7.12 (m, 5H), 5.40 
(d, J = 3.9 Hz, 1H), 5.20 (dt, J = 4.6, 1.0 Hz, 1H), 4.54 (tt, J = 5.3, 2.5 Hz,1H), 2.74-2.60 
(m, 2H), 2.14-2.09 (m, 2H), 1.82-1.71 (m, 2H); 13C NMR (125 MHz, CDCl3) δ128.6, 
128.5, 126.0, 88.1, 83.0, 79.6, 37.9, 34.8, 32.6, 29.7; IR (thin film) 1831, 1600 cm-1; 
m/z: calc. 241.0835 [M+Na], found 241.1585. 
 
Optically Pure 3-Phenethyl-2,6-Dioxabicyclo[3.2.0]heptan-7-one (3.40a/3.40b).  To a 
10 mL flask containing OTMS-QN (9.9 mg, 0.025 mmol) and Mukaiyama’s reagent 
(270 mg, 0.76 mmol) was added 0.2 mL CH2Cl2 and Hünig’s base (0.13 mL, 0.100 
mmol)  Aldehyde acid 3.19 was azeotroped in xylenes prior to reaction then dissolved in 
0.5 mL CH2Cl2 and added to the flask via syringe pump over 1 h.  The solution turned 
from yellow to dark red-brown as the reaction progressed.  The syringe was washed (2 X 
0.25 mL) with CH2Cl2 and the washings added to the flask.  The reaction stirred for 24 h 
at 23 °C then was concentrated in vacuo.  The crude material was directly purified by 
flash column chromatography (2:8 EtOAc:Hexanes) to yield β-lactones 3.40a/3.40b (8.6 
mg. 16%) as colorless oils (dr = 1:1); m/z: calc. 241.0835 [M+Na], found 241.1585. 
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2-(1-(tert-butyldimethylsilyloxy)-5-oxopentan-3-yloxy)acetic acid (3.41).  To a 25 
mL flask was added alkene acid S1 (250 mg, 0.606 mmol) in CH2Cl2 (10 mL).  This was 
cooled to -78°C under N2 for 30 min.  O3 was bubbled through the solution until blue 
color appeared, ̴30 seconds, then O2 was bubbled through for 1 min.  To the solution was 
added dimethylsulfide (380 mg, 0.47 mL, 6.0 mmol).  The solution was allowed to 
slowly warm to 23 °C overnight under N2.  The reaction was quenched with sat’d NaCl 
(20 mL) and the organic layer extracted.  The aqueous phase was washed with 
dichloromethane (2 X 20 mL) and the layers separated.  The organic layers were 
combined, dried over Na2SO4, and concentrated in vacuo.  The crude material was 
purified via flash column chromatography on silica gel (5:2:88 acetone:AcOH:CH2Cl2) 
to yield racemic aldehyde acid 3.41 (180 mg, 72%) as a colorless oil.  3.41: Rf = 0.44 
(EtOAc:Hexanes = 1:4); 1H NMR (500 MHz, CDCl3) δ  9.80 (s, 1H), 7.78 – 7.64 (m, 
4H), 7.54 – 7.35 (m, 6H), 4.19 (s, 2H), 4.02 – 3.70 (m, 2H), 2.75 (dd, J = 7.8, 1.4 Hz, 
2H), 2.68 (d, J = 3.6 Hz, 1H), 2.04 – 1.70 (m, 2H), 1.10 (s, 9H);  13C NMR (125 MHz, 
CDCl3) δ  201.9, 175.1, 135.8, 133.6, 130.2, 128.1, 73.5, 66.8, 60.1, 48.7, 36.7, 27.2, 
19.4; IR (thin film): 3072, 2859, 1728, 1112 cm-1. 
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3-(2-(tert-butyldimethylsilyloxy)ethyl)-2,6-dioxabicyclo[3.2.0]heptan-7-one 
(3.42a/3.42b).  To a 10 mL flask containing tetramisole (34.5 mg, 0.169 mmol) and 
Mukaiyama’s reagent (118 mg, 0.338 mmol) was added 1.5 mL CH2Cl2 and Hünig’s 
base (0.065 mL, 0.371 mmol, 2 equiv).  Racemic aldehyde acid 3.41 (70.0 mg, 0.169 
mmol) was azeotroped in xylenes prior to reaction then dissolved in 1.0 mL CH2Cl2 and 
added to the flask via syringe pump over 1 h.  The solution turned from a yellow to a 
dark red-brown as the reaction progressed.  The syringe was washed (2 X 0.44 mL) with 
CH2Cl2 and the washings added to the flask.  The reaction stirred for 18 h at 23 °C then 
was concentrated in vacuo.  The crude material was taken directly onto purification by 
gradient flash column chromatography (2:8→10:0 EtOAc:Hexanes) to yield β-lactones 
3.42a/3.42b (4.0 mg. 9%) as colorless oils.  3.40a/3.40b: Rf = 0.44 (EtOAc/Hexanes = 
1:4);  1H NMR (300 MHz, CDCl3) δ 7.71-7.65 (m, 5H), 7.45-7.29 (m, 5H), 5.44 (d, J = 
3.8 Hz, 1H), 5.40 (d, J = 4.0 Hz, 1H), 5.24 (t, J = 4.0 Hz, 1H), 5.15 (t, J = 3.82 Hz, 1H), 
4.98-4.93 (m, 1H), 4.39-4.32 (m, 1H), 3.84-3.73 (m, 2H) 3.83-3.79 (m, 2H), 2.38 (d, J = 
1.9 Hz, 2H), 2.33 (d, J = 1.7 Hz, 2H), 2.29-2.24 (m, 2H), 2.24-2.19 (m, 2H), 2.07-1.94 
(m 2H), 1.91-1.81 (m, 2H), 1.63-1.58 (m, 2H), 1.57-1.53 (m, 2H), 1.09(s, 9H), 1.08(s, 
9H);  13C NMR (125 MHz, CDCl3) δ  170.3, 168.8, 135.7, 133.7, 129.9, 127.9, 105.2, 
88.2, 88.0, 81.3, 80.0, 78.7, 60.8, 38.7, 37.0, 34.8, 27.0, 19.4; IR (thin film): 2929, 1836, 
1105 cm-1; m/z: calc. 419.1649 [M+Na], found 419.1892. 
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3-(2-(tert-butyldimethylsilyloxy)ethyl)-2,6-dioxabicyclo[3.2.0]heptan-7-one 
(3.42a/3.42b).  To a 10 mL flask containing tetramisole (34.5 mg, 0.169 mmol) and 
Mukaiyama’s reagent (118.4 mg, 0.338 mmol) was added 1.5 mL CH2Cl2 and Hünig’s 
base (0.118 mL, 0.676 mmol, 4 equiv).  Racemic aldehyde acid 3.19 (70.0 mg, 0.169 
mmol) was azeotroped in xylenes prior to reaction then dissolved in 1.0 mL CH2Cl2 and 
added to the flask via syringe pump over 1 h.  The solution turned from a yellow to a 
dark red-brown as the reaction progressed.  The syringe was washed (2 X 0.44 mL) with 
CH2Cl2 and the washings added to the flask.  The reaction stirred for 18 h at 23 °C then 
was concentrated in vacuo.  The crude material was taken directly onto purification by 
flash column chromatography (1:4 EtOAc:Hexanes).  No desired product was formed.  
Instead, the major products of the reaction were α, β-unsaturated aldehyde 4.1 and α, β-
unsaturated acid 4.2. 
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APPENDIX II 
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